
Migraine is a leading neurological cause of emergency attendance and inpatient admission in the UK. Although most attacks respond to community therapy, a minority develop status migrainosus or medication-overuse headache requiring hospital care. This review summarises evidence-based inpatient strategies aligned with NICE and BASH guidance. Management should begin with intravenous hydration where indicated, parenteral non-steroidal anti-inflammatory drugs, and dopamine-antagonist antiemetics. Triptans remain the first migraine-specific option; valproate and corticosteroids are reserved for refractory attacks. Peripheral nerve blocks and, in tertiary settings, lidocaine or ketamine infusions provide rescue therapy.
Autoimmune pulmonary alveolar proteinosis (APAP) is a rare GM-CSF autoantibody-mediated disease. Here, we report the case of a previously healthy woman who was diagnosed with APAP following two mild episodes of COVID-19, based on a crazy-paving CT pattern, periodic acid–Schiff-positive histology and markedly elevated anti-GM-CSF antibodies. She received no PAP-specific therapy. Months later, a rhinovirus/enterovirus illness occurred. Subsequent follow-up CT showed partial radiological resolution. This case highlights two major aspects: clinicians should consider anti-GM-CSF testing when persistent post-COVID opacities show a crazy-paving pattern, and spontaneous improvement can occur in mild APAP. The temporal associations between the viral infections and the development or improvement of APAP should be interpreted cautiously, as they do not establish causality.
Background Systemic-anticancer-treatment (SACT) near the end of life (EOL) remains common despite limited evidence of meaningful survival benefit and concerns regarding treatment-related toxicity and quality of life. Here, we aimed to identify demographic and clinical factors associated with SACT and continuous intravenous opioid and/or benzodiazepine use at EOL, with a specific focus on adolescent and young adult (AYA) patients. Methods In this retrospective cohort study adult patients with cancer treated with palliative intent at the Medical University of Vienna between 2013 and 2021 were included. SACT at EOL was defined as systemic antineoplastic therapy administered ≤30 days before death. Continuous intravenous opioid and/or benzodiazepine use at EOL was defined as ongoing hydromorphone, morphine and/or midazolam administration via syringe pump at the time of death. Univariable and multivariable logistic regression analyses were performed. A predefined subgroup analysis examined AYA patients (<40 years). Results Among 775 patients (median age 65 years; 51% female, 49% male) 358 (46%) received SACT within 30 days before death. In multivariable analysis, younger age (OR 0.99 per year increase, 95% CI 0.98–1.00, p = 0.043) and male sex (female vs male: OR 0.64, 95% CI 0.48–0.85, p = 0.002) were independently associated with SACT at EOL. In a sensitivity analysis, AYA status was associated with higher odds of SACT (OR 2.32, 95% CI 1.32–4.23, p = 0.004). Continuous intravenous opioid and/or benzodiazepine use at EOL was documented in 343 patients (44%); recent SACT was independently associated with higher odds of medication use (OR 4.93, 95% CI 3.63–6.74, p < 0.001). Among 55 AYA patients (7.1%), SACT (65% vs 45%) and continuous intravenous opioid and/or benzodiazepine use (67% vs 43%) were more frequent than among non-AYA patients aged ≥40 years. Conclusion SACT at EOL remains common and was independently associated with younger age and male sex. AYA patients also showed higher odds of SACT in a sensitivity analysis, although this finding should be interpreted cautiously given the small subgroup size. Higher rates of both interventions among AYA patients highlight the need for early, age- and sex-sensitive palliative care integration.